BriaCell Secures License for a Promising Novel Anti-Cancer Agent
August 04 2022 - 9:00AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:
BCT) (“BriaCell” or the “Company”), a clinical-stage
biotechnology company specializing in targeted immunotherapies for
cancer, announces that it has secured an exclusive license from
University of Maryland, Baltimore County (UMBC) to
develop and commercialize Soluble CD80 (sCD80) as a biologic agent
for the treatment of cancer.
The novel technology, originally developed by
Suzanne Ostrand-Rosenberg, Ph.D., Emeritus Faculty at UMBC, and
member of BriaCell’s scientific advisory board, is titled “Soluble
CD80 as a Therapeutic to Reverse Immune Suppression in Cancer
Patients” and covered under USPN 8,956,619 B2, USPN 9,650,429 B2,
and USPN 10,377,810 B2. In animal models, sCD80 was well-tolerated
and stopped tumor growth by potentially restoring natural
anti-tumor immunity (see Lucas A Horn, et al. and Samuel T Haile et
al. in collaboration with Dr. Ostrand-Rosenberg). Additionally,
strong anti-tumor activity of sCD80 has been reported in multiple
tumor types (see Lucas A Horn, et al.). Importantly, as
demonstrated in the same studies, sCD80’s unique actions may
involve both awakening and boosting the immune system to recognize
and destroy tumor cells.
Under the terms of the agreement, BriaCell gains
the worldwide rights to develop and commercialize sCD80, while UMBC
maintains ownership of the patents. BriaCell will pay royalties to
UMBC upon the commercialization of the product plus patent
management costs. The licensing agreement was coordinated by UMBC’s
Office of Technology Development.
“Our mission has been to develop safe and
effective treatments for cancer patients who do not respond to
existing treatments, and a transformational anti-cancer agent such
as sCD80 may provide us with such an additional opportunity,”
stated Dr. Bill Williams, BriaCell’s President and CEO. “Based on
the promising data in animal studies, we plan to explore the
potential use of sCD80 technology as a therapeutic agent in
combination with our other immunotherapies or on its own. We look
forward to accelerating the development of this novel anti-cancer
agent to bring hope to patients who need it the most.”
About BriaCell Therapeutics
Corp.
BriaCell is an immuno-oncology-focused
biotechnology company developing targeted and effective approaches
for the management of cancer. More information is available at
https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Examples of
forward-looking statements in this news release include, among
others, statements that the Company makes regarding the potential
for development and commercialization of sCD80 as a biologic agent
for the treatment of cancer, and the possibility that sCD80 may
awaken and boost the immune system to recognize and destroy tumor
cells. Forward-looking statements are based on BriaCell’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully under the heading “Risks and
Uncertainties” in the Company's most recent Management’s Discussion
and Analysis, under the heading "Risk Factors" in the Company's
most recent Annual Information Form, and under “Risks and
Uncertainties” in the Company's other filings with the Canadian
securities regulatory authorities and the U.S. Securities and
Exchange Commission, all of which are available under the Company's
profiles on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov. Forward-looking statements contained
in this announcement are made as of this date, and BriaCell
Therapeutics Corp. undertakes no duty to update such information
except as required under applicable law.
Neither Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Aug 2023 to Aug 2024